{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:22:03Z","timestamp":1781968923101,"version":"3.54.5"},"reference-count":21,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>IgA vasculitis (IgAV) can occur after vaccination. We aimed to assess a potential safety signal on the association between coronavirus disease 2019 (COVID-19) vaccines and IgAV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cases of IgAV involving COVID-19 vaccines were retrieved in VigiBase. Disproportionate reporting was assessed using the Bayesian information component (IC) with all other drugs and vaccines as control groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred thirty patients with de novo IgAV from 24 countries were included, mostly from the United States (193\/330, 58%). Fifty percent (163\/328) were female and median age was 32 years (IQR 15-59), of which 33% (84\/254) were young (1-17 yrs). Median time to onset of IgAV was 7 days (IQR 2-16; n = 256) and 85% (280\/330) of patients were vaccinated with mRNA vaccines. Seriousness was reported in 188\/324 (58%) cases. Sixty-five percent (95\/147) recovered and 1% (2\/147) died. A positive rechallenge was reported for 3 of 4 patients (75%). A total of 996 cases of IgAV were identified with other vaccines. There was a small significant increase in IgAV reporting with COVID-19 vaccines compared with all other drugs (IC 0.22, 95% credible interval [CrI] 0.04 to 0.35). No disproportionality signal was found between COVID-19 vaccines and other vaccines (IC \u22121.42, 95% CrI \u22121.60 to \u22121.28). There was no significant difference between mRNA vaccines and viral vector COVID-19 vaccines. Men and children had a significant overreporting of IgAV compared with women and adults, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides reassuring results regarding the safety of COVID-19 vaccines in the occurrence of IgAV compared to other vaccines.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220629","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T13:20:18Z","timestamp":1668518418000},"page":"564-567","source":"Crossref","is-referenced-by-count":19,"title":["COVID-19 Vaccination as a Trigger of IgA Vasculitis: A Global Pharmacovigilance Study"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3421-9954","authenticated-orcid":false,"given":"Yanis","family":"Ramdani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9renger","family":"Largeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie-Pierre","family":"Jonville-Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-5016","authenticated-orcid":false,"given":"Alexandra","family":"Audemard-Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"2023122109250652000_50.4.564.1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"2023122109250652000_50.4.564.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00874-9"},{"key":"2023122109250652000_50.4.564.3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3195"},{"key":"2023122109250652000_50.4.564.4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1573397113666170517155443","article-title":"Vasculitis following influenza vaccination: a review of the literature","volume":"13","author":"Watanabe","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"2023122109250652000_50.4.564.5","doi-asserted-by":"crossref","first-page":"771619","DOI":"10.3389\/fimmu.2021.771619","article-title":"Pathogenesis of IgA vasculitis: an up-to-date review","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"2023122109250652000_50.4.564.6","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.59233"},{"key":"2023122109250652000_50.4.564.7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"2023122109250652000_50.4.564.8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s10067-022-06097-z","article-title":"Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review","volume":"41","author":"Alrashdi Mousa","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2023122109250652000_50.4.564.9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00296-021-05069-x","article-title":"ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review","volume":"42","author":"Prabhahar","year":"2022","journal-title":"Rheumatol Int"},{"key":"2023122109250652000_50.4.564.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.079"},{"key":"2023122109250652000_50.4.564.11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s13730-022-00695-1","article-title":"Development of IgA vasculitis with severe glomerulonephritis after COVID-19 vaccination: a case report and literature review","volume":"11","author":"Sugita","year":"2022","journal-title":"CEN Case Rep"},{"key":"2023122109250652000_50.4.564.12","doi-asserted-by":"crossref","first-page":"102707","DOI":"10.1016\/j.autrev.2020.102707","article-title":"Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach","volume":"20","author":"Rasmussen","year":"2021","journal-title":"Autoimmun Rev"},{"key":"2023122109250652000_50.4.564.13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40264-018-00792-0","article-title":"A comparison study of algorithms to detect drug-adverse event associations: frequentist, Bayesian, and machine-learning approaches","volume":"42","author":"Pham","year":"2019","journal-title":"Drug Saf"},{"key":"2023122109250652000_50.4.564.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"2023122109250652000_50.4.564.15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","article-title":"Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems","volume":"28","author":"Raschi","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2023122109250652000_50.4.564.16","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403604"},{"key":"2023122109250652000_50.4.564.17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.autrev.2015.02.003","article-title":"IgA vasculitis (Henoch-Sh\u00f6nlein purpura) in adults: diagnostic and therapeutic aspects","volume":"14","author":"Audemard-Verger","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2023122109250652000_50.4.564.18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","article-title":"T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"2023122109250652000_50.4.564.19","doi-asserted-by":"crossref","first-page":"793191","DOI":"10.3389\/fimmu.2021.793191","article-title":"Anti-SARS-CoV-2 immunoglobulin isotypes, and neutralization activity against viral variants, according to BNT162b2-vaccination and infection history","volume":"12","author":"Tarkowski","year":"2021","journal-title":"Front Immunol"},{"key":"2023122109250652000_50.4.564.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.009"},{"key":"2023122109250652000_50.4.564.21","doi-asserted-by":"crossref","unstructured":"Mettler C , Terrier B , Treluyer JM , Chouchana L. Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study. Rheumatology 2022;keac323.","DOI":"10.1093\/rheumatology\/keac323"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T17:26:15Z","timestamp":1703179575000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,1]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.3899\/jrheum.220629"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220629","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}